



Vaccination against Babesiosis

Guest Editor:

Dr. Stéphane Delbecq

Centre de Biologie Structurale,
INSERM U1054, CNRS UMR 5048,
Université de Montpellier, 34090
Montpellier, France

Deadline for manuscript
submissions:

closed (7 December 2022)

Message from the Guest Editor

Dear Colleagues,

We wish to publish a Special Issue concerning the state of the art in the field of vaccination against Babesia.

We invite submissions in the form of original research papers or review papers on the topic of your choice in this area. Babesia and babesiosis as a widespread disease, with multiple clinical forms found in multiple host–parasite interactions, have been studied from multiple angles, and we hope to reflect this diversity in our Special Issue. This represents an opportunity to create an overview of current research that could be translated in efficient actions to control parasites in the field, both for human and animal populations.

As a proposal, and among other potential topics, we suggest papers concerning various host and parasite species, ranging from basic science to operational interventions in the field.

Dr. Stéphane Delbecq
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)